- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSISTANT PROFESSOR | Dermatology
- Cancer (Oncology)
- Internal Medicine
- Hospital Affiliations
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
In the News:
Watch Dr. Friedlander discuss a new FDA approved treatment (Erivedge) for Basal Cell Carcinoma:
KTVX-TV (ABC/Salt Lake City, Utah)
KRNV-TV (NBC/Reno, Nevada)
WNAV-AM (Baltimore, Maryland)
- Basal Cell Carcinoma
- Skin Cancer
- Squamous Cell Carcinoma
MD, Columbia University
Internship, Internal Medicine
Columbia-Presbyterian Medical Center
Residency, Internal Medicine
Columbia-Presbyterian Medical Center
Memorial Sloan-Kettering Cancer Center
A Phase II Study of MK-3475 in Patents with Advanced Merkel Cell Carcinoma
The main purpose of this study is to find out how people with advanced Merkel cell cancer respond to a study drug called MK-3475. MK-3475 is an experimental medication that is being used to stimulate your immune system to destroy cancer cells. We will refer to it from here ...
The main purpose of this study is to see if this experimental drug is safe and whether it works to help people with advanced or metastatic basal cell carcinoma. The study drug, wh...
A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma
The study drug is an investigational drug that is being evaluated for the treatment of patients with Merkel cell carcinoma. Investigational means that it has not been approved by the U.S. Food and Drug Administration (FDA) and is still being tested for safety and effectiven...
A Phase 2 Multicenter, Randomized, Open-label, Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
The purpose of this study is to find out more about talimogene laherparepvec when given before surgery in people with advanced melanoma who are eligible for complete surgical removal (excision) of their melanoma. The study will see if talimogene laherparepvec followed by surge...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Friedlander during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.